EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY 4.0

A retrospective study of prognostic factors and prostate-specific antigen dynamics in Japanese patients with metastatic hormone-sensitive prostate cancer who received combined androgen blockade therapy with bicalutamide

Yu Tashiro, Shusuke Akamatsu, Kentaro Ueno, Toshiyuki Kamoto, Naoki Terada, Takuya Hida, Ryoma Kurahashi, Tomomi Kamba, Atsushi Saito, Takumi Lee, Satoshi Morita, Takashi Kobayashi

International Journal of Clinical Oncology · 2024-10 · 29 (10) · 1564-1573

DOI: 10.1007/s10147-024-02597-x ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift International Journal of Clinical Oncology, online erschienen am 17.08.2024. Verfasst von Yu Tashiro und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Japanese Red Cross Otsu Hospital, 1 Chome-1-35 Nagara, Otsu, Shiga, 520-0046, Japan. unity.tashiro@gmail.com. Hauptthemen laut MEDLINE: Anilides, Tosyl Compounds, Nitriles, Prostate-Specific Antigen. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Astellas Pharma Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This retrospective observational study explored the therapeutic potential of combined androgen blockade (CAB) with bicalutamide (Bic-CAB) as an initial treatment for metastatic hormone-sensitive prostate cancer (mHSPC) in Japan.

Methods

The electronic health records of 159 patients with mHSPC from three Japanese institutions who received initial treatment with Bic-CAB between 2007 and 2017 were analyzed. The time to prostate-specific antigen (PSA) progression, duration of Bic-CAB treatment, and overall survival (OS), with various definitions for PSA progression, were assessed. A multivariate Cox proportional hazards model was constructed using clinical parameters to predict time to the end of Bic-CAB treatment and OS.

Results

The median observation period was 46.4 months, and the median age of patients at diagnosis was 71 years. A total of 46.5% patients experienced PSA progression with a median survival duration of 29 months (according to Prostate Cancer Clinical Trials Working Group 3 criteria), and 49.1% patients achieved a PSA nadir < 0.2 ng/mL in a median time of 4.7 months. When stratified by PSA nadir and PSA change, patients at low risk for disease progression with a small PSA change due to low initial PSA had a 5-year OS of 100% and a 10-year OS of 75%. The OS during the observation period was 72.9 months.

Conclusion

These findings highlight the potential effect of Bic-CAB in patients with mHSPC who were at low risk for disease progression. Initial treatment with Bic-CAB and adjusting treatment early based on PSA dynamics may be a reasonable treatment plan for these patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnilidesTosyl CompoundsNitrilesProstate-Specific AntigenAndrogen AntagonistsProstatic NeoplasmsHumansMaleRetrospective StudiesAgedMiddle AgedJapanAged, 80 and overPrognosisAntineoplastic Combined Chemotherapy ProtocolsDisease ProgressionEast Asian People

Stichwörter der Autor:innen

BicalutamideCombined androgen blockageJapanMetastatic hormone-sensitive prostate cancer

Substanzen

AnilidesbicalutamideTosyl CompoundsNitrilesProstate-Specific AntigenAndrogen Antagonists

Autor:innen und Institutionen

  • Department of Urology, Japanese Red Cross Otsu Hospital, 1 Chome-1-35 Nagara, Otsu, Shiga, 520-0046, Japan. unity.tashiro@gmail.com.
  • Department of Urology, Kyoto University Graduate School of Medicine, 54 Shogoinkawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan. unity.tashiro@gmail.com.
  • Department of Urology, Kyoto University Graduate School of Medicine, 54 Shogoinkawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.
  • Department of Urology, Nagoya University Graduate School of Medicine, 2 Chome-1-10 Kitachikusa, Chikusa Ward, Nagoya, Aichi, 464-0083, Japan.
  • Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Yoshidakonoecho, Sakyo Ward, Kyoto, 606-8303, Japan.
  • Department of Urology, University of Miyazaki, Kihara-5200 Kiyotakecho, Miyazaki, 889-1601, Japan.

Förderung

  • Astellas Pharma Inc.

Zitieren

APA

Tashiro, Y., Akamatsu, S., Ueno, K., Kamoto, T., Terada, N., Hida, T., Kurahashi, R., Kamba, T., Saito, A., Lee, T., Morita, S., & Kobayashi, T. (2024). A retrospective study of prognostic factors and prostate-specific antigen dynamics in Japanese patients with metastatic hormone-sensitive prostate cancer who received combined androgen blockade therapy with bicalutamide. International Journal of Clinical Oncology, 29(10), 1564-1573. https://doi.org/10.1007/s10147-024-02597-x

Vancouver

Tashiro Y, Akamatsu S, Ueno K, Kamoto T, Terada N, Hida T, et al. A retrospective study of prognostic factors and prostate-specific antigen dynamics in Japanese patients with metastatic hormone-sensitive prostate cancer who received combined androgen blockade therapy with bicalutamide. International Journal of Clinical Oncology. 2024;29(10):1564-1573. doi:10.1007/s10147-024-02597-x

BibTeX
@article{Tashiro2024,
  author = {Tashiro, Yu and Akamatsu, Shusuke and Ueno, Kentaro and Kamoto, Toshiyuki and Terada, Naoki and Hida, Takuya and Kurahashi, Ryoma and Kamba, Tomomi and Saito, Atsushi and Lee, Takumi and Morita, Satoshi and Kobayashi, Takashi},
  title = {A retrospective study of prognostic factors and prostate-specific antigen dynamics in Japanese patients with metastatic hormone-sensitive prostate cancer who received combined androgen blockade therapy with bicalutamide},
  journal = {International Journal of Clinical Oncology},
  year = {2024},
  volume = {29},
  number = {10},
  pages = {1564--1573},
  doi = {10.1007/s10147-024-02597-x}
}
Kostenlos starten →